A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

AstraZeneca AB

Enrolment target

176

Start

11 Jul 2023

Age 18 Years to any · Sex: All

• —

  Denmark
• —

  Poland
• —

  Czechia
• —

  Netherlands
• —

  Spain
• —

  Germany
• —

  Italy
• —

  Austria
• —

  Sweden